SYNTA PHARMACEUTICALS CORP 4
4 · SYNTA PHARMACEUTICALS CORP · Filed Nov 19, 2015
Insider Transaction Report
Form 4
Gollust Keith R
Director
Transactions
- Sale
Common Stock
2015-11-17$0.41/sh−100,000$41,400→ 2,885,061 total(indirect: By Wyandanch Partners, L.P.)
Holdings
- 175,000(indirect: By IRA)
Common Stock
- 401,764
Common Stock
Footnotes (2)
- [F1]This transaction was executed in multiple trades at prices ranging from $0.4005 to $0.4306 per share. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F2]The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.